4.2 Article

Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease

出版社

WILEY
DOI: 10.1002/ar.21493

关键词

Alzheimer's disease; MCI; MRI; neuropsychology; FreeSurfer

资金

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI)
  2. National Institutes of Health [U01 AG024904, AG000277, P30 AG010129, K01 AG030514]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Abbott
  6. AstraZeneca AB
  7. Bayer Schering Pharma AG
  8. Bristol-Myers Squibb
  9. Eisai Global Clinical Development
  10. Elan Corporation
  11. Genentech
  12. GE Healthcare
  13. GlaxoSmithKline
  14. Innogenetics
  15. Johnson and Johnson
  16. Eli Lilly and Co.
  17. Medpace, Inc.
  18. Merck and Co.
  19. Novartis AG
  20. Pfizer Inc
  21. F. Hoffman-La Roche
  22. Schering-Plough
  23. Synarc, Inc.
  24. Wyeth
  25. Alzheimer's Association
  26. Alzheimer's Drug Discovery Foundation
  27. U.S. Food and Drug Administration, Dana Foundation

向作者/读者索取更多资源

Atrophy within the hippocampus (HP) as measured by magnetic resonance imaging (MRI) is a promising biomarker for the progression to Alzheimer's disease (AD). Subregions of the HP along the longitudinal axis have been found to demonstrate unique function, as well as undergo differential changes in the progression to AD. Little is known of relationships between such HP subregions and other potential biomarkers, such as neuropsychological (NP), genetic, and cerebral spinal fluid (CSF) beta amyloid and tau measures. The purpose of this study was to subdivide the hippocampus to determine how the head, body, and tail were affected in normal control, mild cognitively impaired, and AD subjects, and investigate relationships with HP subregions and other potential biomarkers. MRI scans of 120 participants of the Alzheimer's Disease Neuroimaging Initiative were processed using FreeSurfer, and the HP was subdivided using 3D Slicer. Each subregion was compared among groups, and correlations were used to determine relationships with NP, genetic, and CSF measures. Results suggest that HP subregions are undergoing differential atrophy in AD, and demonstrate unique relationships with NP and CSF data. Discriminant function analyses revealed that these regions, when combined with NP and CSF measures, were able to classify by diagnostic group, and classify MCI subjects who would and would not progress to AD within 12 months. Anat Rec, 2012. (C) 2011 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据